

**IN THE CLAIMS:**

Please cancel claims 1-7, and add the following claims:

(8) A method of treating or preventing allergic and inflammatory conditions of the skin or airway passages in a human in need of such treating or preventing while avoiding a food effect associated with other non-sedating antihistamines which comprises orally administering to said human under feed or fasted conditions an amount of desloratadine effective for such treating or preventing while avoiding a food effect on the bioavailability of desloratadine.

(9) The method of claim 8 wherein the amount of desloratadine is about 2.5 mg/day to about 45 mg/day.

(10) The method of claim 8 wherein the amount of desloratadine is about 2.5 mg/day.

(11) The method of claim 8 wherein the amount of desloratadine is about 5 mg/day to about 10 mg/day.

**BEST AVAILABLE COPY**

(12) The method of claim 8 wherein the amount of desloratadine is about 5 mg/day.

(13) The method of claim 8 wherein the desloratadine is administered in a tablet formulation.

(14) The method of claim 8 wherein the desloratadine is administered in a syrup formulation.

(15) The method of claim 8 wherein the allergic reaction is season allergic rhinitis, pernninal allergic rhinitis, atopic dermatitis, urticaria or allergic asthma.

(16) A method of treating or preventing allergic and inflammatory conditions of the skin or airway passages in a human in need of such treating or preventing a which comprises orally administering to said human an amount of desloratadine effective for such treating or preventing, while obtaining substantially the same bioavailability of desloratadine under feed or fasted conditions.

(17) The method of claim 16 wherein the amount of desloratadine is about 2.5 mg/day to about 45 mg/day.

(18) The method of claim 16 wherein the amount of desloratadine is about 2.5 mg/day.

(19) The method of claim 16 wherein the amount of desloratadine is about 5 mg/day to about 10 mg/day.

**BEST AVAILABLE COPY**

(20) The method of claim 16 wherein the amount of desloratadine is about 5 mg/day.

(21) The method of claim 16 wherein the desloratadine is administered in a tablet formulation.

(22) The method of claim 16 wherein the desloratadine is administered in a syrup formulation.

(23) The method of claim 16 wherein the allergic reaction is season allergic rhinitis, pernninal allergic rhinitis, atopic dermatitis, urticaria or allergic asthma.

(24) A method of treating or preventing seasonal or perennial allergic rhinitis in a human in need of such treating or preventing while avoiding a food effect associated with non-sedating antihistamines which comprises orally administering to said human under feed or fasted conditions an amount of desloratadine effective for such treating or preventing while avoiding a food effect on the bioavailability of desloratadine.

(25) The method of claim 24 wherein the amount of desloratadine is in the range of about 2.5 mg/day to about 45 mg/day.

(26) The method of claim 24 wherein the amount of desloratadine is about 5 mg/day to about 15 mg/day.

(27) The method of claim 24 wherein the amount of desloratadine is about 2.5 mg/day.

(28) The method of claim 24 wherein the amount of desloratadine is about 5 mg/day.

(29) The method of claim 24 wherein the patient is suffering from seasonal allergic rhinitis. ~~DESI~~ ~~AVAILABLE COPY~~

(30) The method of claim 24 wherein the patient is suffering from perennial allergic rhinitis.

(31) The method of claim 24 wherein the desloratadine is administered in a tablet formulation.

(32) The method of claim 24 wherein the desloratadine is administered in a syrup formulation.

(33) A method of treating or preventing seasonal or perennial allergic rhinitis in a human in need of such treating or preventing which comprises orally administering to said human an amount of desloratadine effective for such treating or preventing, while obtaining substantially the same bioavailability of desloratadine under feed or fasted conditions.

(34) The method of claim 33 wherein the amount of desloratadine is in the range of about 2.5 mg/day to about 45 mg/day.

(35) The method of claim 33 wherein the amount of desloratadine is about 5 mg/day to about 15 mg/day.

(36) The method of claim 33 wherein the amount of desloratadine is about 2.5 mg/day.

(37) The method of claim 33 wherein the amount of desloratadine is about 5 mg/day.

(38) The method of claim 33 wherein the patient is suffering from seasonal allergic rhinitis.

(39) The method of claim 33 wherein the patient is suffering from perennial allergic rhinitis.

(40) The method of claim 33 wherein the desloratadine is administered in a tablet formulation.

(41) The method of claim 33 wherein the desloratadine is administered in a syrup formulation.

**BEST AVAILABLE COPY**

(42) A method of treating or preventing atopic dermatitis or urticaria in a human in need of such treating or preventing while avoiding a food effect associated with non-sedating antihistamines which comprises orally administering to said human under feed or fasted conditions an amount of desloratadine effective for such treating or preventing while avoiding a food effect on the bioavailability of desloratadine.

(43) The method of claim 42 wherein the amount of desloratadine is about 2.5 mg/day.

(44) The method of claim 42 wherein the amount of desloratadine is about 5 mg/day to about 15 mg/day.

(45) The method of claim 42 wherein the amount of desloratadine is about 5 mg/day to about 10 mg/day.

(46) The method of claim 42 wherein the amount of desloratadine is about 5 mg/day.

(47) The method of claim 42 wherein the patient is suffering from atopic dermatitis.

(48) The method of claim 42 wherein the patient is suffering from urticaria.

(49) A method of treating or preventing atopic dermatitis or urticaria in a human in need of such treating or preventing a which comprises orally administering to said human an amount of desloratadine effective for such treating or preventing, while obtaining substantially the same bioavailability of desloratadine under feed or fasted conditions.

(50) The method of claim 49 wherein the amount of desloratadine is in the range of about 2.5 mg/day to about 45 mg/day.

(51) The method of claim 49 wherein the amount of desloratadine is about 2.5 mg/day to about 45 mg/day.

(52) The method of claim 49 wherein the amount of desloratadine is about 2.5 mg/day.

(53) The method of claim 49 wherein the amount of desloratadine is about 5 mg/day to about 10 mg/day.

(54) The method of claim 49 wherein the amount of desloratadine is about 5 mg/day.

(55) The method of claim 49 wherein the desloratadine is administered in a tablet formulation.

(56) The method of claim 49 wherein the desloratadine is administered in a syrup formulation.

(57) The method of claim 49 wherein the patient is suffering from atopic dermatitis.

(58) The method of claim 49 wherein the patient is suffering from urticaria.

---

BEST AVAILABLE COPY